CDSCO warns pharma firms over ‘surrogate’ ads for obesity drugs

Summary

India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has warned pharmaceutical companies against direct or indirect promotion of prescription weight-loss medicines, including GLP-1 therapies.

NEW DELHI, March 12, 2026 — India’s top drug regulator has issued an advisory cautioning pharmaceutical firms against promoting prescription obesity drugs through indirect marketing practices such as disease-awareness campaigns, celebrity endorsements and influencer outreach.

The CDSCO said several companies were attempting to circumvent India’s ban on direct-to-consumer advertising of prescription medicines by using “surrogate” promotional strategies.

Focus on GLP-1 therapies

The advisory specifically references GLP-1 receptor agonists such as semaglutide and tirzepatide, which are increasingly used for weight management under medical supervision.

Drugs Controller General of India Rajeev Singh Raghuvanshi said campaigns that exaggerate therapeutic outcomes or underplay the importance of lifestyle interventions could violate provisions of the Drugs and Cosmetics Act, 1940.

The regulator said even awareness campaigns that indirectly create brand recall for prescription medicines would be treated as unlawful advertising.

Crackdown on indirect marketing

The CDSCO flagged multiple formats under scrutiny:

• Disease-awareness campaigns linked to specific drug outcomes
• Influencer-led content describing weight-loss journeys using medication
• Outdoor advertising in public spaces such as malls and airports

The advisory also stressed that prescription drugs must not be promoted to the public through digital or social channels.

New compliance requirements

To strengthen oversight, CDSCO directed manufacturers to:

• Display authorised contact details and office codes clearly in prescribing information
• Establish consumer grievance mechanisms with dedicated helplines
• Submit updated Risk Management Plans (RMPs) as prescriptions rise

Timing amid generic expansion

The move comes ahead of the expected patent expiry of semaglutide in India later this month, which could open the market to multiple domestic generic manufacturers.

Regulators said stricter enforcement is aimed at preventing inappropriate use as availability increases.

Why this matters

• Public safety: Limits inappropriate demand for prescription-only drugs
• Regulatory clarity: Reinforces India’s ban on DTC pharmaceutical advertising
• Market transition: Prepares oversight ahead of expected generic launches

FAQs

Q1. Which drugs are affected?

The advisory applies to GLP-1 receptor agonists such as semaglutide and tirzepatide and their generic versions.

Q2. Why is disease-awareness advertising restricted?

Because some campaigns indirectly promote specific medicines and create consumer demand.

Q3. What penalties could firms face?

Violations may attract action under the Drugs and Cosmetics Rules, including license suspension.

Q4. When does semaglutide lose patent protection in India?

The key patent is expected to expire later in March 2026.

Q5. Can influencers promote prescription drugs?

No. CDSCO considers influencer promotion a form of indirect advertising.